TY - JOUR
T1 - Poor adherence is the main reason for loss of ccyr and imatinib failure for chronic myeloid leukemia patients on long-term therapy
AU - Ibrahim, Amr R.
AU - Eliasson, Lina
AU - Apperley, Jane F.
AU - Milojkovic, Dragana
AU - Bua, Marco
AU - Szydlo, Richard
AU - Mahon, Francois Xavier
AU - Kozlowski, Kasia
AU - Paliompeis, Christos
AU - Foroni, Letizia
AU - Khorashad, Jamshid S.
AU - Bazeos, Alex
AU - Molimard, Mathieu
AU - Reid, Alistair
AU - Rezvani, Katayoun
AU - Gerrard, Gareth
AU - Goldman, John
AU - Marin, David
PY - 2011/4/7
Y1 - 2011/4/7
N2 - We studied the relation between adherence to imatinib measured with microelectronic monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) and of imatinib failure in 87 CCyR chronic myeloid leukemia patients receiving long-term therapy. We included in our analysis the most relevant prognostic factors described to date. On multivariate analysis, the adherence rate and having failed to achieve a major molecular response were the only independent predictors for loss of CCyR and discontinuation of imatinib therapy. The 23 patients with an adherence rate less than or equal to 85% had a higher probability of losing their CCyR at 2 years (26.8% vs 1.5%, P= .0002) and a lower probability of remaining on imatinib (64.5% vs 90.6%, P= .006) than the 64 patients with an adherence rate more than 85%. In summary, we have shown that poor adherence is the principal factor contributing to the loss of cytogenetic responses and treatment failure in patients on long-term therapy.
AB - We studied the relation between adherence to imatinib measured with microelectronic monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) and of imatinib failure in 87 CCyR chronic myeloid leukemia patients receiving long-term therapy. We included in our analysis the most relevant prognostic factors described to date. On multivariate analysis, the adherence rate and having failed to achieve a major molecular response were the only independent predictors for loss of CCyR and discontinuation of imatinib therapy. The 23 patients with an adherence rate less than or equal to 85% had a higher probability of losing their CCyR at 2 years (26.8% vs 1.5%, P= .0002) and a lower probability of remaining on imatinib (64.5% vs 90.6%, P= .006) than the 64 patients with an adherence rate more than 85%. In summary, we have shown that poor adherence is the principal factor contributing to the loss of cytogenetic responses and treatment failure in patients on long-term therapy.
UR - http://www.scopus.com/inward/record.url?scp=79953823237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953823237&partnerID=8YFLogxK
U2 - 10.1182/blood-2010-10-309807
DO - 10.1182/blood-2010-10-309807
M3 - Article
C2 - 21346253
AN - SCOPUS:79953823237
SN - 0006-4971
VL - 117
SP - 3733
EP - 3736
JO - Blood
JF - Blood
IS - 14
ER -